Nektar Therapeutics at TD Cowen Healthcare Conference Transcript
Marc Frahm from the biotech team here at TD Cowen. We're really happy to have with us now, for the next session, from Nectar Therapeutics, JZ, who the Chief R&D officer. The plan is JZ is going to do maybe 10,15 minutes of slides, kind of level set things for everybody in the room or on the webcast, and then we will, do Q&A from there. So with that, I'll hand it over to JZ.
Thank you so much. Good morning everyone. We're excited to be here at Nektar and excited to share with you some of the upcoming developments, recent developments at our company and kind of where we are and looking ahead to 2026, 2027, and beyond.
Today I'll just cover a few slides sharing our progress and there's some forward-looking statements. One of the things that's important for us at Nektar is we've had a transformation. We've really retooled ourselves focusing on our expertise in immunology, both in terms of the research,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
